287121-28-2

Upstream product

• 233755-46-9 methyl 1-(2-furanylcarbonyl)-4-(4-hydroxybenzenesulfonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 
• 764-01-2 methyl propargyl alcohol 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 287121-33-9 methyl 2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-3-hydroxypropanoate 
• 522623-55-8 2-[(2-amino-benzyl)-(4-but-2-ynyloxy-benzenesulfonyl)-amino]-3-hydroxy-propionic acid methyl ester 
• 527-69-5 2-furancarbonyl chloride 
• 287121-25-9 methyl 4-(4-but-2-ynyloxybenzenesulfonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 

Downstream Products

• 287121-29-3 4-(4-But-2-ynyloxybenzene-sulfonyl)-1-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylic acid 

Relevant academic research and scientific papers

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

Benzodiazepine inhibitors of the MMPs and TACE. Part 2

A series of benzodiazepine MMP/TACE inhibitors bearing polar moieties has been synthesized in an effort to optimize inhibitory activity against LPS-stimulated TNF production in human monocytes and oral activity in a murine LPS model.